ライフサイエンスコーパス: blood test

1 creening test of which 83% chose the Septin9 blood test.

2 strated the feasibility of an IBM diagnostic blood test.

3 nclusion, MPV is easily available in routine blood test.

4 he improved safety of a noninvasive maternal blood test.

5 help identify cancer patients using a simple blood test.

6 nclusion, PDW is easily available in routine blood test.

7 nt abnormalities found in the results of any blood test.

8 r disease, and may be identified by a simple blood test.

9 ility by monitoring tumor progression with a blood test.

10 sitivity and specificity of the fecal occult blood test.

11 mmonly used platelet parameters from routine blood test.

12 quality of life, anxiety/depression, or any blood test.

13 llary investigations, mainly MRI and routine blood tests.

14 n imaging, and cerebrospinal fluid (CSF) and blood tests.

15 ata were collected from routine preoperative blood tests.

16 d for a medical consultation and a series of blood tests.

17 treatment recommendations using non-invasive blood tests.

18 erformance characteristics than fecal occult blood tests.

19 84 years in average health with fecal occult blood tests.

20 eding, as evidenced by positive fecal occult blood tests.

21 lso received physical examinations and basic blood tests.

22 , neuroradiological, neuropsychological, and blood tests.

23 nual or biennial screening with fecal occult-blood testing.

24 ometry), comprehensive echocardiography, and blood testing.

25 ed by monitoring response to therapy through blood testing.

26 ars, cholesterol screening, and fecal occult blood testing.

27 d referred as many as 5 for interviewing and blood testing.

28 s for widespread screening with fecal occult blood testing.

29 rement of platelet number as part of routine blood testing.

30 tically investigated using sputum, urine and blood testing.

31 tially reduced sensitivity compared to whole-blood testing.

32 be lower than that with guaiac fecal occult blood testing.

33 hematochezia (19%) or positive fecal occult blood test (15%).

34 lood glucose measurement (41%), fecal occult blood testing (39%), and chest radiography (36%), were d

35 thy women aged 70-74 years with fecal occult blood tests, 431 women aged 75-79 years in poor health w

36 The participants perceived blood testing (49.9%) to be more accurate than OF testin

37 s (11.8%), or a positive result from a fecal blood test (5.5%).

38 atio, 1.32; 95% CI, 1.19-1.45), but not with blood testing (53% vs 45%; aOR, 1.18; 95% CI, 0.96-1.46)

39 90 selected the Septin9 blood test (83%), 16 selected a stool test (15%) and 3 r

40 Non-MRI techniques, including baseline blood tests, abdominal ultrasonography in children, mamm

41 related adverse events, serious arrhythmias, blood test abnormalities, or death.

42 hospital based on seven routinely undertaken blood tests (albumin, creatinine, haemoglobin, potassium

43 nction between LTBI and active TB based on a blood test alone.

44 ble substitutes for traditional fecal occult blood testing, although modeling may be needed to determ

45 ear test, 2) a mammogram, 3) a faecal occult blood test and 4) a prostate specific antigen test.

46 1 healthy young Caucasians whose 35 clinical blood test and anthropometric indices matched the medica

47 antly with worseing pathology, findings from blood test and clinical outcomes; rates of conversion an

48 t validated risk adjustment Tree model using blood test and NEWS taken within +/-24 hours of admissio

49 bined one-time screening with a fecal occult-blood test and sigmoidoscopy identified 75.8 percent of

50 Marked eosinophilia in a blood test and sputum, poorly defined centrilobular nodu

51 od that PE is present, followed by a D-dimer blood test and/or CTPA.

52 improve patient compliance with fecal occult blood testing and colorectal cancer screening in general

53 cal trials to reduce mortality: fecal occult blood testing and flexible sigmoidoscopy.

54 in which they were offered routine clinical blood testing and ileocolonoscopy; 322 were screened by

55 Fecal occult-blood testing and sigmoidoscopy have been recommended fo

56 Combining fecal occult blood testing and sigmoidoscopy may decrease mortality a

57 ed the three specimen cards for fecal occult-blood testing and underwent a complete colonoscopic exam

58 Participants had repeat blood testing and were administered a questionnaire on r

59 All patents had fasting blood tests and anthropometric measures at the time of l

60 TCDC toxicity was evaluated by liver blood tests and by assessing mitochondrial lipid peroxid

61 lectron beam computed tomography and fasting blood tests and cardiovascular risk factors were obtaine

62 Selected blood tests and clinical risk factors provide a scoring

63 Initial blood tests and history were thought possibly to suggest

64 and after 1 year, patients underwent routine blood tests and measurement of CAC, BMD, and novel serum

65 We explored the use of routine blood tests and national early warning scores (NEWS) rep

66 3248 emergency admissions with a full set of blood tests and NEWS with an in-hospital mortality of 5.

67 hed men and women with negative fecal occult-blood tests and no family history of colon cancer.

68 s to assess the relationship between routine blood tests and outcomes using a Cox proportional hazard

69 Routine blood tests and routine lumbar punctures are usually unn

70 How well do biochemical blood tests and serologic measures of fibrosis predict t

71 ts with chronic hepatitis C, and biochemical blood tests and serologic tests currently have only mode

72 events (version 4.0) on the basis of serial blood tests and the attending physician's report.

73 reasonable variations in the direct costs of blood tests and the blood itself, or the probability or

74 isease in the differential of abnormal liver blood tests and to be aware of the clinical implications

75 (about 30%) did not have a full set of index blood tests and/or NEWS and so were not included in our

76 ue to withdrawal based on refusal to provide blood tests) and were not included in the analyses.

77 rasound, or magnetic resonance imaging), any blood test, and ED length of stay, adjusted for visit ac

78 LOI can be assayed with a DNA-based blood test, and it may be a valuable predictive marker o

79 ls support the use of screening fecal occult blood testing, and case-control studies support the use

80 ons were associated with older age, abnormal blood tests, and abnormal vital signs.

81 48-h ambulatory electrocardiography, fasting blood tests, and clinical examination.

82 ectrocardiograms, 24-hour Holter monitoring, blood tests, and completion of Minnesota Living with Hea

83 history of heavy alcohol use, findings from blood tests, and exclusion of other liver diseases by bl

84 re (blood pressure measurement, urine tests, blood tests, and information on complications), as well

85 ceived a liver biopsy, lifestyle assessment, blood tests, and QOL tools, including the Chronic Liver

86 Clinical examination, blood tests, and upper endoscopy were done before random

87 aging (aOR, 1.21; 95% CI, 0.96-1.53), or any blood test (aOR, 1.02; 95% CI, 0.79-1.33), but had longe

88 A variety of methodological approaches to blood testing are under development, with different leve

89 Routine blood tests are an integral part of clinical medicine an

90 Many blood tests are moderately useful for identifying clinic

91 Blood tests are more readily available, with less cost a

92 Blood tests are needed to identify steroid-resistant (SR

93 acceptability include the perception that a blood test at health centre level represents improvement

94 Infants of infected women had blood tested at 0 and 1 month by microscopy, PCR and imm

95 mptom assessment, clinical examinations, and blood tests at 3- to 4-month intervals for 2 years, with

96 intention to treat among women who had study blood tests at 34 weeks.

97 P-gp activity in the blood-brain barrier and blood-testes barrier.

98 ly in this organ, given the existence of the blood-testes barrier.

99 A noninvasive whole-blood test based on gene expression and demographic char

100 Here, we report a blood test, based on the simultaneous quantization of fo

101 Blood test-based measures or left ventricular ejection f

102 s, yet the majority reported that they order blood tests before patients start these therapies and on

103 Additional data from fasting blood tests better identified those at extreme risk.

104 t might form the foundation for new clinical blood tests, but to date their contribution to the diagn

105 We performed weekly surveillance blood testing by quantitative polymerase chain reaction

106 dipstick testing, urine cultures, and simple blood tests can provide direction.

107 rticipants collected 3 stools, smeared fecal blood test cards and used same-day shipment to a central

108 example, simplifying access to fecal occult blood test cards), or made system-level changes (for exa

109 NAlater Stabilization Solution, fecal occult blood test cards, and fecal immunochemical test tubes).

110 dergo limited occult-cancer screening (basic blood testing, chest radiography, and screening for brea

111 ntions, and expands on the findings of prior blood tests conducted on this group of patients.

112 Blood tests confirmed no evidence of autoimmune or viral

113 A simple blood test could aid the front-line physician in this ta

114 positive titer >/=1 in 40, cholestatic liver blood tests, diagnostic or compatible liver histology).

115 Safety assessment included blood tests, documentation of adverse events at regular

116 whether PSP is superior to other established blood tests (e.g. White Blood Count, Neutrophils or C -

117 a standardized baseline assessment with CMR, blood test, echocardiography, and 6-minute walk test and

118 More blood tests (eg, total cholesterol, odds ratio [OR] 1.88

119 Additional diagnostic tests include blood tests (erythrocyte sedimentation rate, ESR; C-reac

120 sigmoidoscopy every 5 years and fecal occult blood testing every year (FS/FOBT) or colonoscopy every

121 Blood tests excluded viral, metabolic, and autoimmune di

122 All patients underwent blood tests, exhaled nitric oxide (FeNO), sputum inducti

123 Conventional blood tests fail to offer real-time unambiguous visualiz

124 ing with sensitive guaiac-based fecal occult blood testing, fecal immunochemical testing (FIT), multi

125 synchronous combination of FibroScan with a blood test (FibroMeter) provided a new detailed (six cla

126 ly with reported performance of fecal occult blood testing, flexible sigmoidoscopy, and barium enema.

127 atus using 3 strategies: annual fecal occult blood tests, flexible sigmoidoscopy every 5 years, or co

128 providers use only the digital fecal occult blood test (FOBT) as their primary screening test.

129 t for colorectal neoplasia; the fecal occult blood test (FOBT) detects neoplasias with low levels of

130 The use of the fecal occult blood test (FOBT) for colorectal cancer (CRC) screening

131 g by fecal DNA testing (F-DNA), fecal occult blood testing (FOBT) and/or sigmoidoscopy, or colonoscop

132 graphy, Papanicolaou tests, and fecal occult blood testing (FOBT) but not colonoscopy, flexible sigmo

133 ar of life saved), using annual fecal occult blood testing (FOBT) combined with flexible sigmoidoscop

134 py or sigmoidoscopy (year 1) or fecal occult blood testing (FOBT) in year 1 and FOBT, colonoscopy, or

135 s either sensitive unrehydrated fecal occult blood testing (FOBT) or fecal immunochemical testing (FI

136 white men was annual rehydrated fecal occult blood testing (FOBT) plus sigmoidoscopy (followed by col

137 o have negative attitudes about fecal occult blood testing (FOBT), but not about flexible sigmoidosco

138 only flexible sigmoidoscopy and fecal occult blood testing (FOBT).

139 cancer by use of guaiac-based faecal occult blood tests (FOBT) reduces disease-specific mortality.

140 ng Programme (asymptomatic but faecal occult blood testing [FOBt] positive).

141 Rates of patient completion of fecal occult blood tests (FOBTs) are often low.

142 Consecutive rounds of fecal occult blood tests (FOBTs) are used to screen for colorectal ca

143 Fecal occult blood tests (FOBTs), flexible sigmoidoscopy, or colonosc

144 population within 1 year using fecal occult blood testing followed by diagnostic colonoscopy for pos

145 These initial studies provide a prototype blood test for diagnosis of vCJD in symptomatic individu

146 Anemia was measured with a blood test for hemoglobin.

147 A blood test for HVPG could be performed in cirrhosis pati

148 82% of the original 1133 subjects underwent blood test for IgE and answered the questionnaire, respe

149 Currently, a blood test for lung cancer does not exist.

150 tivity diary that was temporally linked to a blood test for measurement of 25(OH)D concentration.

151 suspected of having mesothelioma, a positive blood test for mesothelin at a high-specificity threshol

152 A blood test for PAD, if sufficiently sensitive and specif

153 findings show that PMCA might be useful as a blood test for routine, live animal diagnosis of CWD.

154 t detection assay, developed originally as a blood test for vCJD, for the detection of disease-associ

155 The result of a blood test for vCJD, the Direct Detection Assay for vCJD

156 Women randomised to the MMS group had their blood tested for CA125 and those randomised to the USS g

157 ubjects kept a 3-d food record and had their blood tested for metabolic risk factors.

158 Of these, 749 (77%) had blood tested for S. pneumoniae.

159 This study provides evidence that blood testing for circulating tumor genetic markers may

160 physiologic studies of nerve and muscle, and blood testing for creatine kinase, genetic disorders, an

161 Blood testing for endogenous small metabolites to determ

162 ed optical transducer to allow point-of-care blood testing for risk stratifications of cardiac patien

163 notransferase and bilirubin levels, standard blood tests for causes of hepatitis and cirrhosis other

164 notransferase and bilirubin levels, standard blood tests for causes of hepatitis other than drug toxi

165 Inexpensive blood tests for diabetes, thyroid dysfunction, and vitam

166 Since thyroglobulin, no new blood tests for differentiated thyroid cancer (DTC) have

167 sitivity and specificity of these peripheral blood tests for predicting the absence of bone marrow ir

168 isit included history, physical examination, blood tests for renal, lipid, glucose profiles, and 24-h

169 Most PCPs have access to blood tests for total and specific IgE.

170 less invasive tests (sigmoidoscopy or occult blood tests) for lower-risk persons and colonoscopy for

171 e tools (clinical decision rules and D-dimer blood tests) for patients with low pretest probability a

172 ening every 3 years plus annual fecal occult blood testing had an ICER of more than $100,000 per life

173 s, or every 5 years with annual fecal occult blood testing, had an ICER of less than $55,600 per life

174 Many blood tests have been proposed as alternatives to liver

175 ults of tests for inflammation (stool occult blood testing [Hemoccult], fecal leukocytes, fecal lacto

176 ollection, physical examination, biochemical blood tests, hormone levels, transthoracic Doppler echoc

177 5% CI: 1.31, 1.45) but not with fecal occult blood test (HR, 1.00; 95% CI: 0.91, 1.10) than those wit

178 nce interval (CI): 1.17, 2.19), fecal occult blood tests (HR=1.31, 95% CI: 1.12, 1.53), screening mam

179 annual highly sensitive guaiac fecal occult blood testing (HSFOBT), annual fecal immunochemical test

180 with respect to 116 traits assessed through blood tests, hypertonic saline challenge tests, question

181 We tested a novel simple and rapid blood test in 30 patients with GLUT1-DS with predominant

182 l samples with the Hemoccult II fecal occult-blood test in average-risk, asymptomatic persons 50 year

183 of colon cancer and had not had fecal occult blood testing in the past year or flexible sigmoidoscopy

184 sis using additional adjustment for selected blood tests in a subgroup of 182,792 ICU episodes lowere

185 needed for primary care on the use of liver blood tests in detection of early disease and the need f

186 ot aware of any guidelines for monitoring by blood tests in RA patients treated with biologic agents,

187 Baseline thrombogenic blood tests included 6 hemostatic variables (D-dimer, fi

188 Blood tests included cytokines, clotting factors, apolip

189 Blood tests included measurements of 25-hydroxyvitamin D

190 An extensive series of blood tests including serum amylase were serially checke

191 Blood tests, including vitamin E, B(12), folate, lead, a

192 Blood tests indicated no evidence of toxicity.

193 ion that can be used to perform fecal occult blood tests, interpret the results of those tests, and p

194 ctal cancer (CRC) by the guaiac fecal occult blood test, interval cancers develop in 48% to 55% of th

195 accurately classified patients with a single blood test into rule-out or rule-in categories: Net Recl

196 (1) Dichotomise the blood tests into normal/abnormal or (2) use the actual v

197 T-qPCR however, this enzyme-free, isothermal blood test is amenable to incorporation into low-cost po

198 While this rapid and sensitive blood test is certainly valuable in the appropriate sett

199 n resistance reflected in R values from this blood test is higher for patients with AD, DM2, and FTD

200 ere a highly reliable and minimally invasive blood test is lacking.

201 enge because an accurate, minimally invasive blood test is lacking.

202 ring life by tonsil biopsy, a prion-specific blood test is needed to assess and manage this potential

203 d by offering non-invasive tests, and that a blood test is the preferred option should be validated i

204 Fecal occult blood testing is a popular screening test because of its

205 If occult blood testing is done, clinicians must decide how to int

206 Although fecal occult-blood testing is the only available noninvasive screenin

207 ves and high false negatives of fecal occult blood testing lead to high costs and low cost-effectiven

208 A new 1,3 beta-glucan blood test may assist is the definition of invasive fung

209 with IPMNs and suggest that an lncRNA-based blood test may have utility as a diagnostic adjunct for

210 Selected blood tests may be useful in the diagnosis of venous thr

211 vaccination; foot examination; and each of 3 blood tests measuring glucose control, cholesterol level

212 Blood test monitoring, including toxicology screening, l

213 ated to hazardous prescribing and inadequate blood-test monitoring of medicines 6 months after the in

214 ial screening with guaiac-based fecal occult blood testing (n = 419,966) showed reduced CRC-specific

215 nical lab tests between one company offering blood tests obtained from finger prick (Theranos) and 2

216 n pathways altered by insulin using a single blood test offers confidence in the current approach.

217 Further blood testing often reveals a range of changes affecting

218 The effect of screening with fecal occult-blood testing on colorectal-cancer mortality persists af

219 y, systemic inflammatory biomarkers, ex vivo blood tests on immunoreactivity to lipopolysaccharide (L

220 cancer include sensitive guaiac fecal occult blood test or fecal immunochemical test.

221 utive patients with a positive faecal occult blood test or previous adenomas undergoing surveillance

222 was detected by screening using fecal occult blood testing or evaluation of symptoms.

223 Fecal occult blood testing or flexible sigmoidoscopy was ordered for

224 mmend for or against routine use of hormonal blood tests or hormonal treatment in the management of p

225 sk Force endorse screening with fecal occult blood tests or sigmoidoscopy.

226 ts taking biotin supplements before ordering blood tests or when interpreting results.

227 ), or having undergone a recent fecal occult blood test (OR, 13.69; 95% CI: 3.66, 51.29).

228 gs from screening tests (urinary dipstick or blood tests), or when symptoms become severe.

229 , using clinical interviews, questionnaires, blood tests, or a combination of these methods.

230 cal and systemic toxicity was assessed using blood tests, organ weights, and histology.

231 Among blood-tested participants included at age 38 years, mean

232 s indicated that the AmpliSens DBS and whole-blood tests performed equally well and were comparable t

233 rrelated linearly (r .47) with the number of blood tests performed in both study periods.

234 C tuberculosis (TB) test if symptomatic, POC blood tests, physical exam, education, counseling, and a

235 ty of one-time screening with a fecal occult-blood test plus sigmoidoscopy.

236 stic yield supported the use of fecal occult blood testing plus sigmoidoscopy.

237 Reasons for blood test preference included convenience of an office

238 In randomized trials, fecal occult-blood testing reduces mortality from colorectal cancer.

239 c indications, such as positive fecal occult blood test result (OR, 0.33; 95% CI, 0.19-0.57), surveil

240 art of clinical medicine and in interpreting blood test results clinicians have two broad options.

241 Dichotomising routine blood test results is less accurate in predicting in-hos

242 Methotrexate improved most blood test results more than colchicine.

243 Although the physical examination and blood test results were normal, the evacuee mothers rate

244 Biomarkers based on standard blood test results would be useful in research, drug dev

245 Following analysis of recent and previous blood test results, a diagnosis of chronic benign neutro

246 uding demographic details, weight follow-up, blood test results, and information on medications and c

247 ta, clinical manifestations at presentation, blood test results, EUS and ERCP findings, and clinical

248 We used routine blood test results, length of hospital stay, and 30-day

249 rmine if colchicine or methotrexate improves blood test results, symptoms, and/or liver histology in

250 s of asymptomatic adults with positive fecal blood test results.

251 Midlands, England, with a full set of index blood tests results (albumin, creatinine, haemoglobin, p

252 Blood tests revealed a remarkable increase in eosinophil

253 Blood tests revealed significantly decreased erythrocyte

254 ese guidelines recommend annual fecal occult blood test screening plus periodic flexible sigmoidoscop

255 the first screening round of a faecal occult blood test screening programme in a single geographical

256 who have positive results on a fecal occult blood test should have a full colonic examination.

257 vestigation of the synovial fluid as well as blood tests should be undertaken immediately to establis

258 Routine blood tests showed lactic acidosis and mild elevation of

259 illustrated efficacy, including fecal occult blood testing, sigmoidoscopy and colonoscopy.

260 r of screening tests, including fecal occult blood tests, sigmoidoscopy, double-contrast barium enema

261 se of either annual or biennial fecal occult-blood testing significantly reduces the incidence of col

262 nt comprehensive screening with stool occult blood testing, standard upper gastrointestinal endoscopy

263 We conclude that a blood test that measures unmethylated INS DNA serves as

264 Recently, a novel in vitro blood test that provides an overall measure of calcifica

265 the routine updating of serologic and other blood tests that may be relevant to the posttransplant c

266 FN-gamma release assays (IGRAs) are in vitro blood tests that measure T-cell release of IFN-gamma aft

267 colonography, the guaiac-based fecal occult blood test, the fecal immunochemical test, the multitarg

268 MI, elevations in a simple, widely available blood test, the WBC count, were associated with impaired

269 sitive reaction on guaiac-based fecal occult-blood tests, the relative frequency of upper gastrointes

270 TSHR mRNA also represents a new blood test to aid assessment of disease status in thyroi

271 and demonstrates the feasibility of using a blood test to detect lung parenchymal damage.

272 dings are a promising basis for developing a blood test to diagnose and predict the occurrence of MDS

273 ents with a B-type natriuretic peptide (BNP) blood test to identify those with depressed left ventric

274 adaptation of an established vCJD diagnostic blood test to urine.

275 Blood tests to detect circulating tumor cells (CTC) offe

276 eat strategy, in which individuals are given blood tests to determine whether they are chronically in

277 Currently, rapid blood tests to diagnose EBOV infection include the antig

278 acteristics, cause of disease, liver-related blood tests, tumour characteristics, treatments, last fo

279 ing 10,050 emergency admissions with routine blood tests undertaken within 24 hours of admission.

280 ces to merit case-note review and diagnostic blood tests, unless an obvious explanation is found.

281 We devised guidelines to optimize blood tests utilization, and designed this study to quan

282 Further research into the use of actual blood test values in clinical decision making is require

283 ted that the gene expression profiling (GEP) blood test was noninferior to EMB between 6 and 60 month

284 A very sensitive blood test was used to capture circulating tumor cells (

285 r the laboratory-based model, which required blood testing, we used standard risk factors to assess r

286 py, flexible sigmoidoscopy, and fecal occult blood test were 27.9, 0.6, and 29.5 per 1000 person-year

287 Blood tests were normal, except for the elevation of pla

288 Blood tests were obtained at trial completion.

289 MRI at 30 minutes and 60 minutes, and repeat blood tests were performed at 60 minutes for the patient

290 Fasting blood tests were performed at regular time intervals dur

291 ces performed for routine blood sampling; no blood tests were performed solely for the purpose of the

292 n the transcriptional signatures measured by blood tests were readily detectable just 2 weeks after t

293 Colonoscopy and blood tests were the "first line" diagnostic tools.

294 from three consecutive days for fecal occult-blood testing, which were rehydrated for interpretation.

295 mily history), a full examination, and basic blood tests, which include the erythrocyte sedimentation

296 group of patients with positive fecal occult-blood tests who were referred for further evaluation, fr

297 and muscle degeneration, and develop an IBM blood test with high diagnostic accuracy.

298 One-time screening with both a fecal occult-blood test with rehydration and sigmoidoscopy fails to d

299 markers are obtained intermittently through blood testing with long delay.

300 5) or the combination of annual fecal occult blood testing with sigmoidoscopy every 5 years are viabl